Navigation Links
Genomma Lab International Announces Second Quarter 2009 Results
Date:7/23/2009

MEXICO CITY, July 23 /PRNewswire/ -- Genomma Lab International, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company"), announced today its results for the quarter ended June 30, 2009. All figures included herein were prepared in accordance with Mexican GAAP; figures are stated in nominal Mexican pesos. Also, the following consolidated figures show the Company's Spanish operations reclassified as discontinued operations according to Mexican GAAP.

2Q09 Highlights (vs. 2Q08)

  • Net Sales reached Ps. 985.5 million, an increase of 50.7%.
  • Gross Profit was Ps. 724.8 million, an increase of 46.1%.
  • EBITDA(1) reached Ps. 256.9 million, an increase of 36.5%.
  • Consolidated Net Income of Ps. 122.9 million, an increase of 3.3%.
  • Earnings per Share(2) increased 16.8% to Ps. 1.03.
  • International Net Sales rose to Ps. 130.1 million, an increase of 220.9%.
  • During the second quarter, Genomma Lab successfully launched three products under three existing brands (Base Brands(3) and Prior Year Launches(4)) as part of the line extension strategy.
  • The Company also launched, during the second quarter, six products under six New Brands(5) as part of its new product launch plan.
  • As of June 30, 2009 the Company had a net cash position of Ps. 1,214.4 million.
  • During the second quarter of 2009, the Company acquired the brand of lotions Flor de Naranja Sanborns(MR), the brand of creams Teatrical, the brand of hair coloring Henna Egipcia, and a 99 year license for the use of Sanborns(MR) brands for the acquired brands.
  • Additionally, during the second quarter, the Company acquired the Jockey Club brand of men's personal care products. All of these brands are well-recognized brands in their respective markets and have been very popular among Mexican consumers for several decades.

(1) EBITDA is calculated by adding pre-operative expenses, depreciation and amortization to the operating income.

(2) Earnings per share are for the last 12 months and were calculated using the weighted average number of shares outstanding for the period.

(3) As defined later in the document.

(4) As defined later in the document.

(5) As defined later in the document.

Comments from the Chairman and CEO

Mr. Rodrigo Herrera, Chairman of the Board and Chief Executive Officer, stated: "We are pleased to report our second quarter 2009 results, which showed a sound growth. We are currently experiencing a challenging economic environment, which has made difficult the Global Economy's performance; therefore, we will continue to proceed with caution. We were, once again, pleasantly surprised by the net sales level registered during this quarter; which proves that both the Company's business model, as well as its advertising strategies, continue to be successful. We expect to continue in this manner so as to continue gaining market share, increasing net sales and profitability, and thus, creating value for our shareholders.

During the second quarter of 2009, we acquired several brands, some of them are expected to strengthen our presence in certain categories, whereas others will allow us to enter new categories. We continue analyzing new initiatives, and remain committed to the growth-by-acquisitions strategy established in our Initial Public Offering. We believe that adverse economic conditions can contribute to finding attractive expansion opportunities for the Company."

For the complete version of this earnings report, please visit: www.genommalab.com

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing over-the-counter pharmaceutical and personal care products companies in Mexico. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Through a combination of a successful new products development process, consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model, the Company had net sales of Ps. 2,629.4 million and EBITDA of Ps. 691.1 million in 2008.

Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker symbol "LAB.B"

(Bloomberg: labb.mx).

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Webcast Alert: Genomma Lab Internacional, S.A.B. de C.V. Announces Second Quarter 2009 Results Conference Call
2. Genomma Lab Internacional Acquires Brands Flor de Naranja Sanborns(MR), Teatrical and Henna Egipcia From Grupo Sanborns
3. Genomma Lab Internacional Announces First Quarter 2009 Results
4. Genomma Lab Acquires the Mexican Company Medicinas y Medicamentos Nacionales
5. Genomma Lab Internacional Announces Fourth Quarter and Full Year 2008 Results
6. Webcast Alert: Genomma Lab Announces Fourth Quarter 2008 Earnings Webcast
7. Genomma Lab Announces Updated Fourth Quarter 2008 Guidance
8. Genomma Lab, New Participant in Market-Maker Program
9. Genomma Lab Announces Initiation of Stock Repurchase Fund
10. Genomma Lab Announces the Successful Launch of the Ma Evans Brand
11. Genomma Lab Announces 2009 Earnings Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... Focused ... innovation in the industry, according to the recent NEJM Catalyst Insights Report on ... of the NEJM Catalyst Insights Council, a qualified group of U.S. executives, clinical ...
(Date:2/18/2017)... ... 2017 , ... A new directory from the Senior Veterans ... connect elderly veterans of America's armed forces to a range of senior care ... on this year's increase in the Veterans Pension with Aid & Attendance for ...
(Date:2/17/2017)... ... 2017 , ... For the first time, International Scholarship and ... floor for the 2017 HIMSS Conference & Exhibition at the Orange ... than 40,000 healthcare industry professionals are expected at the conference, where they will ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access today ... Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) will ... used electronic patient signatures solution in healthcare . , Since it first ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer diagnostics workflow solution provider ... 20 – 22 in San Francisco. As part of the Tri-Conference expo, which ... workflow solution, as well as its new precision medicine platform, “Crosswalk Insight: Oncology™.” ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for ... Vincent J. Angotti has been appointed ... company,s board of directors, effective Monday, March 6, ... experience leading executive and commercial teams at public ...
(Date:2/16/2017)... , Feb. 16, 2017  Prescription pain medications ... department visit are necessary for long-term opioid use to ... Feb. 16 th edition of The New ... "Emergency physicians see more patients in acute pain than ... Parker , MD, FACEP, president of the American College ...
(Date:2/16/2017)... Research and Markets has announced the addition of the ... Function, Application, Cancer Type, Technology - Forecast to 2025" report ... ... grow at a CAGR of around 28.6% over the next decade ... Some of the prominent trends that the market is witnessing include ...
Breaking Medicine Technology: